Evidence map›Paper›PMID 42593489›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Tolerability of [

Korbinian Krieger, Ana Katrina Mapanao, Julie Bolcaen, Kristel Kegler, Peter Bernhardt, Nicholas P van der Meulen, Ulli Köster, Alin Chirindel, Guillaume P Nicolas, Roger Schibli and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Korbinian Krieger *Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Ana Katrina Mapanao *PSI Center for Life Sciences, Villigen‑PSI, Switzerland.
Julie BolcaenPSI Center for Life Sciences, Villigen‑PSI, Switzerland.
Kristel KeglerAnaPath Services Ltd, Liestal, Switzerland.
Peter BernhardtDepartment of Medical Radiation Sciences, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nicholas P van der MeulenPSI Center for Life Sciences, Villigen‑PSI, Switzerland.
Ulli KösterInstitut Laue-Langevin, Grenoble, France.
Alin ChirindelDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Guillaume P NicolasDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Roger SchibliDepartment of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Cristina MüllerDepartment of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland. cristina.mueller@psi.ch.ORCID http://orcid.org/0000-0001-9357-9688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe successful preclinical efficacy studies prompted a Phase I clinical trial to investigate [

methodsThe time-dependent tissue distribution profiles of [

resultsOrgan uptake and absorbed doses were severalfold higher for SibuDAB than for PSMA-I&T and terbium-161 delivered about 40% higher organ doses than lutetium-177. Kidney accumulation of radioligands was mainly localized in the renal cortex and blockable with excess ligand in the case of PSMA-I&T but not for SibuDAB. In Study I, leukocyte and erythrocyte levels remained comparable between treated and control mice. Thrombocyte counts remained stable with PSMA-I&T radioligands, while SibuDAB radioligands caused 23-28% decrease by Day 10, with full recovery seen for [

conclusionHematological changes were transient, but more pronounced after the application of SibuDAB than of PSMA-I&T, most likely due to the prolonged blood circulation. Other organs and tissues remained unaffected by any of the applied treatments. Substituting lutetium-177 with terbium-161 did not significantly alter the measured parameters. It remains to be demonstrated clinically whether

Indexed as

Albumin-binderProstate cancerPSMARadioligand therapyTerbium-161

Identifiers

PMID42593489

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.